LACTNET Archives

Lactation Information and Discussion

LACTNET@COMMUNITY.LSOFT.COM

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
"Ellen Penchuk, IBCLC" <[log in to unmask]>
Reply To:
Lactation Information and Discussion <[log in to unmask]>
Date:
Fri, 29 Dec 2006 12:12:13 -0500
Content-Type:
text/plain
Parts/Attachments:
text/plain (77 lines)
Thought that you all would be interested in this abstract in Nutrition:

http://www.nutritionjrnl.com/article/PIIS0899900706003595/abstract

Clinical evaluation of a new starter formula for infants containing live 
Bifidobacterium longum BL999 and prebiotics

Giuseppe Puccio, M.D.a, Cinzia Cajozzo, M.D.a, Ferdinando Meli, M.D.a, 
Florence Rochat, Ph.D.b, Dominik Grathwohl, M.Sc.b, Philippe Steenhout, M.D.c

Abstract
Objectives
The larger number of bifidobacteria in the intestine of breast-fed infants has 
been associated with their better health compared with formula-fed infants. 
We assessed the safety and tolerability of an experimental formula containing 
2 × 107 colony-forming units of Bifidobacterium longum BL999 and 4 g/L of a 
prebiotic mixture containing 90% galacto-oligosaccharides and 10% fructo-
oligosaccharides.

Methods
A 7-mo prospective, randomized, reference-controlled, double-blinded trial 
was performed in infants who were not breast fed after the 14th day of birth. 
One hundred thirty-eight infants were enrolled and assigned to receive the 
control or experimental formula until they were 112 d old. Mean weight gain 
(primary outcome) and recumbent length, head circumference, tolerability 
(gastrointestinal symptoms), and overall morbidity (secondary outcomes) were 
measured at 14, 28, 56, 84, and 112 d of age.

Results
Equivalence in mean weight gain between the two groups was shown. The 
treatment difference in the intention-to-treat and per-protocol populations 
were within the predefined equivalence boundaries of ±3.9 g/d. No statistically 
significant difference in recumbent length, head circumference, or incidence of 
adverse events was found between the two groups. Infants in the 
experimental group had fewer incidences of constipation and had stool 
characteristics that suggest that the experimental formula was tolerated well. 
Furthermore, these infants showed a trend toward fewer respiratory tract 
infections.

Conclusions
The starter formula containing BL999 and galacto-oligosaccharides/fructo-
oligosaccharides is safe and well-tolerated.

Keywords: Bifidobacterium longum, Probiotics, Galacto-oligosaccharides/fructo-
oligosaccharides, Prebiotics, Infants, Formula, Safety
a Neonatology, Institute of Obstetrics and Gynecology, University of Palermo, 
Palermo, Italy

b Nestlé Research Center, Lausanne, Switzerland

c Nestlé Nutrition, Nestec Ltd., Vevey, Switzerland

Corresponding author. Tel.: +39-091-655-2016; fax: +39-091-655-2042.

 This study was sponsored by Nestlé Nutrition, Nestec Ltd., Vevey, 
Switzerland.

PII: S0899-9007(06)00359-5



Why does it amaze/confuse me that parents would allow their babies to be 
test subjects? 

Ellen Penchuk, IBCLC, RLC

             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET email list is powered by LISTSERV (R).
There is only one LISTSERV. To learn more, visit:
http://www.lsoft.com/LISTSERV-powered.html

ATOM RSS1 RSS2